Perrigo (NYSE:PRGO) Updates FY 2025 Earnings Guidance

Perrigo (NYSE:PRGOGet Free Report) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 2.900-3.100 for the period, compared to the consensus estimate of 3.020. The company issued revenue guidance of $4.4 billion-$4.5 billion, compared to the consensus revenue estimate of $4.6 billion. Perrigo also updated its FY25 guidance to $2.90-3.10 EPS.

Analysts Set New Price Targets

PRGO has been the subject of several recent research reports. Piper Sandler downgraded shares of Perrigo from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $34.00 to $27.00 in a research note on Monday, January 6th. Argus cut Perrigo from a “buy” rating to a “hold” rating in a research report on Tuesday, January 14th. Finally, StockNews.com lowered Perrigo from a “buy” rating to a “hold” rating in a report on Wednesday, February 19th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $35.00.

Get Our Latest Stock Report on Perrigo

Perrigo Price Performance

PRGO stock traded up $4.55 during trading on Friday, hitting $28.68. The stock had a trading volume of 5,785,025 shares, compared to its average volume of 1,491,685. The company’s 50 day moving average price is $24.87 and its two-hundred day moving average price is $26.18. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.77 and a current ratio of 2.56. The stock has a market cap of $3.91 billion, a price-to-earnings ratio of -24.56 and a beta of 0.54. Perrigo has a 1-year low of $23.14 and a 1-year high of $33.46.

Perrigo (NYSE:PRGOGet Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.01. The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.20 billion. Perrigo had a negative net margin of 3.64% and a positive return on equity of 7.38%. On average, sell-side analysts forecast that Perrigo will post 2.56 EPS for the current fiscal year.

Perrigo Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 25th. Investors of record on Friday, March 7th will be given a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a yield of 4.05%. This is a positive change from Perrigo’s previous quarterly dividend of $0.28. The ex-dividend date is Friday, March 7th. Perrigo’s payout ratio is presently -99.15%.

Insider Transactions at Perrigo

In related news, Director Jeffrey B. Kindler sold 17,598 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $28.27, for a total value of $497,495.46. Following the completion of the transaction, the director now directly owns 5,409 shares of the company’s stock, valued at $152,912.43. This trade represents a 76.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.40% of the stock is currently owned by company insiders.

About Perrigo

(Get Free Report)

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.

See Also

Earnings History and Estimates for Perrigo (NYSE:PRGO)

Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.